Transition from Hybrid Capture 2 to Cobas 4800 in Hpv detection: sensitivity and specificity for Cin2+ in two time periods

Bottari, Fabio; Boveri, Sara; Iacobone, Anna Daniela; Gulmini, C; Igidbashian, Sarah; Cassatella, Maria Cristina; Landoni, Fabio; Sandri, Maria Teresa

doi:10.1080/23744235.2018.1441538

Cited by 6 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that the coincidence rate of the Cobas HPV test and HC2 test was 90% in the primary screening for cervical cancer. Similar results were performed in the researches of other scholars using Cobas HPV and HC2 test [15, 16]. In addition, the Cobas HPV positive rate and HPV16/18 typing positive rate had a U-shaped distribution with age were presented in our study, and there were two peak age groups, 20–29 years old and 60+ years old.…”

Section: Discussionsupporting

confidence: 90%

The performance of Cobas HPV test for cervical cancer screening in Chinese female migrant workers

Wen-ting

Guo

et al. 2021

Epidemiol. Infect.

View full text Add to dashboard Cite

This study aimed to evaluate the performance of Cobas HPV test in cervical cancer screening. A total of 3,442 women aged ≥20 years used Cobas HPV and hybrid capture 2 (HC2) tests were included in this study. Women with any positive result were examined by liquid-based cytology (LBC) test. Then subjects with abnormal LBC or positive Cobas HPV16/18 were further checked up by colposcopy to observe the visible lesions to perform the pathological examination. Of these 3,442 women, 328 cases were Cobas HPV positive, and the positive rate was 9.53% [95% confidence intervals (CI), 8.50%-10.53%]. The positive rate of HPV16, HPV18, and other 12 types of high-risk HPV were 1.54% (95%CI, 1.12%-1.95%), 0.55% (95%CI, 0.30%-0.80%), and 7.44% (95%CI, 6.56%-8.32%), respectively. The coincidence rate of Cobas HPV test and HC2 test was 90% (95%CI, 89.00%-91.00%; Kappa = 0.526) in the primary screening. Age had a non-linear relationship with Cobas HPV positive rate (χ 2 = 4.240, P = 0.040) and HPV16/18 typing positive rate (χ 2 = 6.610, P = 0.010).Compared with the LBC test, the Cobas HPV test had higher sensitivity when detecting patients with high cervical intraepithelial neoplasia (CIN2+ and CIN3+).

show abstract

Section: Discussionsupporting

confidence: 90%

The performance of Cobas HPV test for cervical cancer screening in Chinese female migrant workers

Wen-ting

Guo

et al. 2021

Epidemiol. Infect.

View full text Add to dashboard Cite

show abstract

“…The cobas ® 4800 assay has been approved by the US-FDA for use as a stand-alone assay for the screening of cervical cancer [41]. The cobas ® 4800 assay has been clinically evaluated and has significant sensitivity for the detection of CIN2+ lesions [20,21,42]. Moreover, all steps of the cobas ® 4800 assay could be completed on a fully automated machine.…”

Section: Discussionmentioning

confidence: 99%

“…Although various HPV-DNA detection tests exist, the five US Food and Drug Administration (US FDA)-approved assays detect only the HR-HPV types [18,19]. It has been reported that HR-HPVs testing showed a significant sensitivity for detecting CIN2+ lesions [20][21][22]. Some national cervical cancer screening programs rely solely on HPV primary testing [23,24].…”

Section: Introductionmentioning

confidence: 99%

“…The US FDA-approved HPV-DNA detection assays include cobas ® 4800, Hybrid Capture 2 (HC2) and three others [18,19]. Most studies have compared cobas ® 4800 to the HC2 assay, revealing good concordance [21,[25][26][27]. One study reported that the cobas ® 4800 assay showed higher sensitivity, specificity, and reproducibility than the HC2 assay [28].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High-Risk Human Papillomavirus Detection via Cobas® 4800 and REBA HPV-ID® Assays

Liewchalermwong

Oranratanaphan

Termrungruanglert

et al. 2022

Viruses

View full text Add to dashboard Cite

Persistent infection with high-risk human papillomaviruses (HR-HPVs), particularly HPV16 and 18, has long been known to induce cervical cancer progression. However, given that a minority of HPV-infected women develop cancer, analysis of HR-HPV-infected women could help to predict who is at risk of acquiring cervical cancer. Therefore, to improve HR-HPVs detection, we used the FDA-approved cobas® 4800 HPV and REBA HPV-ID® HPV assays to detect HR-HPVs in colposcopy-derived cervical cells from 303 patients, detecting 72.28% (219) and 71.62% (217) of HR-HPVs positive cases, with HPV16 detection rates of 35.64% (108) and 30.69% (93), respectively. Of the HPV16-positive cases, cobas® 4800 and REBA HPV-ID® identified 28.81% (51) and 25.42% (45) of the CIN1 cases, and 55% (33) and 50% (30) of the 60 CIN2/3 cases, respectively. HPV-diagnostic concordance was 82.17% overall (kappa = 0.488), 87.45% for HR-HPVs (kappa = 0.689), and 88.33% for CIN2/3 (kappa = 0.51). The HR-HPVs detection rates of these assays were comparable. Our findings reveal that the FDA-approved HR-HPVs detection assay is appropriate for screening women with HR-HPVs infection, and for predicting increased risk of cervical cancer progression. REBA HPV-ID® can be used to detect low risk-HPV types in high-grade cervical lesions that are HR-HPV negative as well as in the distribution of HPV types.

show abstract

Screening Methods for Cervical Cancer

Li,

Adobo,

Shi

et al. 2024

ChemMedChem

View full text Add to dashboard Cite

Cervical cancer seriously affects the health of women worldwide. Persistent infection of high‐risk HPV (Human Papilloma Virus) can lead to cervical cancer. There is a great need for timely and efficient screening methods for cervical cancer. The current screening methods for cervical cancer are mainly based on cervical cytology and HPV testing. Cervical cytology is made of Pap smear and liquid‐based cytology, while HPV testing is based on immunological and nucleic acid level detection methods. This review introduces cervical cancer screening methods based on cytology and human papillomavirus testing in detail. The advantages and limitations of the screening methods are also summarized and compared.

show abstract

Transition from Hybrid Capture 2 to Cobas 4800 in Hpv detection: sensitivity and specificity for Cin2+ in two time periods

Cited by 6 publications

References 22 publications

The performance of Cobas HPV test for cervical cancer screening in Chinese female migrant workers

The performance of Cobas HPV test for cervical cancer screening in Chinese female migrant workers

High-Risk Human Papillomavirus Detection via Cobas® 4800 and REBA HPV-ID® Assays

Screening Methods for Cervical Cancer

Contact Info

Product

Resources

About